Acupuncture
Aleksey Radchenko, Certified specialist in acupuncture
Homeopathy
Svetlana Laputjko, Specialist in homeopathy
Psychotherapy
Psychotherapist Alexander Moshkin
Atmest smēķēšanu
Caurdurt ausis
  about us specialists price-list contact us   lv ru en  
DiagnosticsTreatmentBemer-Therapy


ROS ROS
                           


   news News of medicine. 2012 | Archive
 
 

Interferon-Free Hepatitis C Trial Achieves 82% Viral Cure

 
 

23/04/2012
According to new data from the largest Phase II interferon-free trial to date, after only 28 weeks of treatment, almost 82% of hepatitis C patients achieved a viral cure.

The results were achieved in patients with two frequent types of hepatitis C, i.e. HCV genotypes-1a CC and -1b, and will be presented at The International Liver CongressTM at the 47th Annual Meeting of the European Association of the Study of the Liver (EASL), in Barcelona on Saturday 21st April.

Hepatitis C is a viral disease caused by the hepatitis C virus (HCV). It mainly affects the liver and is a leading cause of chronic liver disease and liver transplants. Worldwide, around 170 million people suffer from chronic HCV infections, with 3 to 4 million new infections being diagnosed every year.

Overall, only around 20 to 45% patients manage to achieve a viral cure during the acute phase of the disease, whilst 20% of the remaining chronically infected patients will develop liver cirrhosis within an average of 20 years, and the mortality rate of HCV patients with liver cirrhosis is 2 to 5% per year.

At present, liver damage caused by HCV is the leading cause of chronic liver disease, leading to liver failure and end-stage liver disease, which is the major reason for liver transplants in the Western world. Therefore, an early viral cure for HCV is vital in order to minimize long-term liver damage.

The phase II trial involved 362 patients, including those patients with advanced liver disease. All participants were administered with the interferon-free combination of two investigational compounds, the once-a-day protease inhibitor BI 201335 and the polymerase inhibitor BI 207127. Both drugs were administered with and without ribavirin and with different lengths of treatments.

The outcome demonstrated that 68% of all participants, including those with the most difficult to treat HCV type genotype-1a non-CC, achieved a viral cure after 28 weeks of treatment. Most significantly, 82% of patients with the most common HCV types in Europe and Asia, i.e. genotypes-1a CC and -1b also achieved a viral cure after 28 weeks of therapy. The unique findings in patients with the most common HCV types suggest that interferon could potentially be eliminated in future, however, at present interferon still has to be administered with all treatment options.

HCV has a minimum of six distinct genotypes, i.e. different sequences of the virus, which are identified by a number. Patients with HCV genotype-1 (GT1) are known to be the most difficult to cure. Genotypes have more than 50 subtypes, which are identified by a lowercase letter. An individual's own genetic make-up, represented by uppercase letters like CC, non-CC or CT, is another determining factor in whether treatment will be successful.

Leading researcher Stefan Zeuzem, M.D., Chief of the Department of Medicine and Professor of Medicine at the Johann Wolfgang Goethe University Hospital in Frankfurt, Germany declared:
"Eliminating interferon from HCV treatment is an urgent need. Releasing patients from the side effects and the lengthy treatment commitment seen with interferon would be a huge advance. Such treatments would minimize the impact on patients' lives, and may encourage them to start and stay on treatment, to achieve the ultimate goal of a virologic cure."

Interferon can have severe side effects, including heart failure, sepsis, leucopenia, which is a decrease of white blood cells and loss of vision. The results demonstrated that Boehringer Ingelheim's interferon-free combination therapy was generally well tolerated amongst all five participant groups in the SOUND-C2 trial. Plans of the Phase III clinical trial program are currently underway to further investigate interferon-free combination therapies BI 201335 and BI 207127 efficacy and safety in genotype-1 patients.

Professor Klaus Dugi, Corporate Senior Vice President Medicine at Boehringer Ingelheim declared:
"We very much look forward to the final results from this study, that we hope will be a significant step towards an interferon-free future for patients with HCV. Our commitment to the millions of people around the world who are chronically infected with HCV is to deliver simpler and better tolerated solutions to treatment, including for those with traditionally difficult to cure virus types."

 
   
 

medicalnewstoday.com

 
 
 
 
 
E-APTIEKA  THAT You searched, possibly HERE >>> E-Shop of Health
 
   

Vivasan profilaktiska zobu pasta

10.00 €

Profilaktiska zobu pasta 4-1 ar ēterisko eļļu kompozīciju (apelsīns, piparmētra, lavanda, neļķe, citrons, timiāns, pistācija, tējas koks, manuka, kanuka) efektīvai mutes dobuma kopšanai – smaganu stiprināšanai, kariesa rašanās, zobakmens veidošanās, krākšanas profilaksei.
Efektīvi tīra zobus, dezinficē mutes dobumu, novērš nepatīkamas smakas veidošanos un atsvaidzina elpu.
Stiprina smaganas, paātrina asinsriti balsenes mīkstajos audos, atvieglo elpošanu, veicina krākšanas mazināšanos.
Lietošana: 1-3 reizes dienā.
Tilpums 75 ml

   

Ljapko aplikators lūks Skorohod

53.00 €

Ljapko aplikators lūks "Skorohod"
"Adatainais dakteris" uzlabo garastāvokli, miegu, līdzsvaro vielumaiņas procesus, palielina darbaspējas un dzīves tonusu.
Jāatceras, ka pirmo sāpju reakciju aizstāj patīkama siltuma sajūta, uzlabojas asinsrite, labvēlīgi tiek ietekmēta cilvēka iekšējo orgānu darbība. Aplikatoru efektīva iedarbība balstās ne tikai uz vienkāršu mehānisku iedarbību uz ādu. Adatiņas efektīvi ietekmē reflektorās zonas un akupunktūras punktus.

Ljapko aplikators dod apbrīnojamus rezultātus pateicoties galvaniskās strāvas impulsam, kad adatas saskaras ar ādu, izsaucot mikroelektroforēzes efektu. Tā organismā nonāk labām dzīvības funkcijām nepieciešami metāli: cinks, varš, dzelzs, niķelis un sudrabs.

Lietošana: pirmo piecu minūšu lietošanas laikā relatīvi nepatīkamā diskomforta sajūta no aplikatora adatiņu iedarbības mainās un, rodoties spēcīgam siltumam, kļūst par komfortablu sajūtu, patīkamām „vibrācijām”, durstīšanu. Pēc tam var rasties vispārēja atslābuma sajūta, miegainība, kas reizēm pāriet veselīgā, pilnvērtīgā miegā.
• Pretsāpju, tonizējošam efektam, darba spēju palielināšanai (dienā), kā arī novājinātiem pacientiem un bērniem aplikatora darbības laiks 5 – 7 minūtes;
• Izteiktu sāpju novēršanai, miega efektam (vakarā) – 15 –  30 minūtes. 
Aplikatoriem jāizraisa tikai patīkamas sajūtas. Aplikatora adatiņas, saskaroties ar ādu, to neievaino. Ljapko aplikatorus var izmantot jebkurā vecumā.

 


Ražotājs: „Ljapko” Ukraina.

 

 

trauma or stroke    Svetlana Laputko    neuroses    Aleksey Radchenko    Psychoanalysis    children and adolescents    teenagers    psychiatrist    intervertebral disks    Acupuncture    Igor Shelegov    Acupuncture   Alexander Moshkin    neuroses    Svetlana Laputko    sonography    ultrasonography    Aleksey Radchenko    Igor Shelegov    Acupuncture   Alexander Moshkin   Acupuncture   intervertebral disks    trauma or stroke    Svetlana Laputko    neuroses    Psychoanalysis    Aleksey Radchenko    Igor Shelegov    psychiatrist    intervertebral disks    Acupuncture   Alexander Moshkin    Svetlana Laputko    children and adolescents    teenagers    Acupuncture   intervertebral disks    trauma or stroke    Aleksey Radchenko    neuroses    neuroses    Igor Shelegov    Psychoanalysis    sonography    Acupuncture    ultrasonography   Acupuncture   Alexander Moshkin    children and adolescents    teenagers    Acupuncture    psychiatrist    intervertebral disks    neuroses   intervertebral disks    trauma or stroke    sonography    neuroses    Svetlana Laputko    Psychoanalysis    children and adolescents    Aleksey Radchenko    teenagers    Igor Shelegov    Acupuncture   Alexander Moshkin    Acupuncture    Svetlana Laputko    ultrasonography   

All rights are protected. © 'ROS' Ltd, 2008
PULS.LV Professional statistical system       Europuls.eu - Catalog of the European Internet resources      Яндекс.Метрика Auraj studio карта сайта